Mr Richard Todd Budenz, MPH, PA-C | |
2372 Maritime Dr, Elk Grove, CA 95758-3639 | |
(916) 478-0112 | |
Not Available |
Full Name | Mr Richard Todd Budenz |
---|---|
Gender | Male |
Speciality | Pain Medicine - Pain Medicine |
Location | 2372 Maritime Dr, Elk Grove, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356999007 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0000X | Pain Medicine - Pain Medicine | 57123 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Richard Todd Budenz, MPH, PA-C 1525 Tamarack Rd, West Sacramento, CA 95691-5123 Ph: (209) 598-4175 | Mr Richard Todd Budenz, MPH, PA-C 2372 Maritime Dr, Elk Grove, CA 95758-3639 Ph: (916) 478-0112 |
News Archive
Individualised treatment for each breast cancer patient could soon become a reality, according to Breast Cancer Campaign.
Psychiatrists and GPs increasingly combine mirtazapine with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-noradenaline reuptake inhibitor) antidepressant for patients whose depression does not respond to a single antidepressant.
The seventh meeting in the "Emergence and Convergence" series jointly organized by La Fondation IPSEN and Nature brings together today in San Antonio (Texas, USA) leading experts to discuss concepts emerging from gene regulation studies in immune cells that have led to insights into the initiation and maintenance of epigenetic chromatin marks necessary for proper differentiation and function of these cells in the immune system.
As summer approaches, most people step up skin protection from harmful ultraviolet rays, yet aren't as vigilant about their eyes. Optometrists at the University of Houston are involved in a campaign to change this way of thinking.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 5 days ago